{"id":"fixed-dose-combination-therapy","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fixed dose combinations are designed to improve patient compliance, optimize dosing ratios, and potentially reduce pill burden by delivering multiple drugs in one tablet or capsule. The specific mechanism depends on the individual components and their therapeutic targets, which are not specified for this generic category.","oneSentence":"A fixed dose combination therapy combines two or more active pharmaceutical ingredients in a single formulation to enhance therapeutic efficacy through synergistic or complementary mechanisms.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:46:33.736Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT03686124","phase":"PHASE1, PHASE2","title":"ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2019-05-14","conditions":"Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult","enrollment":375},{"nctId":"NCT07266831","phase":"PHASE2, PHASE3","title":"A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-18","conditions":"Human Immunodeficiency Virus Type 1 (HIV-1) Infection","enrollment":570},{"nctId":"NCT04223791","phase":"PHASE3","title":"Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-18","conditions":"HIV Infection","enrollment":643},{"nctId":"NCT06628310","phase":"PHASE2","title":"A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-12-13","conditions":"Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma","enrollment":180},{"nctId":"NCT04235777","phase":"PHASE1","title":"Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-13","conditions":"Urothelial Cancer, Bladder Cancer, Genitourinary Cancer","enrollment":100},{"nctId":"NCT06694454","phase":"PHASE1, PHASE2","title":"Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma","enrollment":60},{"nctId":"NCT04303117","phase":"PHASE1, PHASE2","title":"PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-13","conditions":"Kaposi Sarcoma","enrollment":80},{"nctId":"NCT07492914","phase":"PHASE2","title":"Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-03-20","conditions":"Resected Head and Neck Cancer","enrollment":30},{"nctId":"NCT07141511","phase":"PHASE1","title":"A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy Adults","status":"COMPLETED","sponsor":"BeOne Medicines","startDate":"2025-09-24","conditions":"Healthy Volunteers","enrollment":24},{"nctId":"NCT07281924","phase":"PHASE1, PHASE2","title":"Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2026-04","conditions":"Metastatic Melanoma, Liver Metastases","enrollment":15},{"nctId":"NCT03937830","phase":"PHASE2","title":"Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-03-10","conditions":"Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma","enrollment":27},{"nctId":"NCT07489625","phase":"EARLY_PHASE1","title":"Hydromorphone With Electroacupuncture and Ear Acupoint Pressing for Refractory Cancer Pain","status":"NOT_YET_RECRUITING","sponsor":"Qinghai Red Cross Hospital","startDate":"2026-03-07","conditions":"Refractory Cancer Pain, Cancer Pain","enrollment":30},{"nctId":"NCT05929664","phase":"PHASE2","title":"Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2023-07-05","conditions":"Locally Advanced Basal Cell Carcinoma, Basal Cell Carcinoma","enrollment":70},{"nctId":"NCT06457919","phase":"PHASE1, PHASE2","title":"A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-06-04","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT03899155","phase":"PHASE2","title":"Pan Tumor Rollover Study","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2019-08-09","conditions":"Cancer","enrollment":1500},{"nctId":"NCT06712563","phase":"","title":"Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-04-17","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2000},{"nctId":"NCT06985485","phase":"PHASE2","title":"Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-05-17","conditions":"Acute Lymphoblastic Leukemia, Immunotherapy, Blinatumomab","enrollment":26},{"nctId":"NCT06820463","phase":"PHASE2","title":"A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-04-24","conditions":"Metastatic Colorectal Cancer","enrollment":390},{"nctId":"NCT06769698","phase":"PHASE2","title":"A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-03-31","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":120},{"nctId":"NCT06827236","phase":"PHASE1, PHASE2","title":"A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-04-23","conditions":"Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer","enrollment":380},{"nctId":"NCT07320963","phase":"PHASE1, PHASE2","title":"Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-31","conditions":"Nasopharyngeal Carcinoma","enrollment":52},{"nctId":"NCT04579367","phase":"","title":"Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2021-01-15","conditions":"Hypercholesterolemia, Mixed Dyslipidemia","enrollment":5000},{"nctId":"NCT07481058","phase":"PHASE2","title":"KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer","status":"RECRUITING","sponsor":"Beijing Konruns Pharmaceutical Co., Ltd.","startDate":"2025-12-12","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":60},{"nctId":"NCT07486726","phase":"PHASE1, PHASE2","title":"Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2026-03-15","conditions":"Acute Myeloid Leukemia (AML), Relapse Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia (AML)","enrollment":112},{"nctId":"NCT07190248","phase":"PHASE3","title":"A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-10-08","conditions":"Non-small Cell Lung Cancer","enrollment":675},{"nctId":"NCT06786767","phase":"","title":"Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting","status":"COMPLETED","sponsor":"Chiesi Bulgaria","startDate":"2025-02-01","conditions":"Asthma, Asthma Patients, Asthma Bronchiale","enrollment":281},{"nctId":"NCT07482059","phase":"PHASE1, PHASE2","title":"A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2026-02","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":33},{"nctId":"NCT07474649","phase":"PHASE3","title":"A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events","status":"NOT_YET_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2026-06-01","conditions":"Coronary Atherosclerosis, Mixed Dyslipidemia, Hypercholesterolemia","enrollment":103},{"nctId":"NCT04338269","phase":"PHASE3","title":"A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2020-07-28","conditions":"Carcinoma, Renal Cell","enrollment":522},{"nctId":"NCT01577082","phase":"PHASE3","title":"Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-04-20","conditions":"Asthma","enrollment":542},{"nctId":"NCT07480850","phase":"PHASE2","title":"Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-01","conditions":"Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":40},{"nctId":"NCT03499704","phase":"PHASE4","title":"A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy","status":"COMPLETED","sponsor":"Celltrion Pharm, Inc.","startDate":"2020-02-11","conditions":"Diabetes Mellitus, Type 2","enrollment":133},{"nctId":"NCT06531798","phase":"PHASE4","title":"Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-19","conditions":"Moderate to Severe COPD","enrollment":150},{"nctId":"NCT05636514","phase":"PHASE1","title":"Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS","status":"RECRUITING","sponsor":"Clinical Hub for Interventional Research (CHOIR)","startDate":"2022-12-14","conditions":"Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia","enrollment":12},{"nctId":"NCT07340827","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)","status":"RECRUITING","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2026-02-05","conditions":"Infertility","enrollment":333},{"nctId":"NCT06671587","phase":"PHASE4","title":"iGlarLixi CGM Study in Chinese T2D Individuals After OADs","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-12-10","conditions":"Type 2 Diabetes (T2D)","enrollment":678},{"nctId":"NCT06993844","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Ensem Therapeutics","startDate":"2025-06-10","conditions":"Advanced Solid Tumors, Advanced Breast Cancer","enrollment":233},{"nctId":"NCT04802759","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-06-22","conditions":"Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer","enrollment":316},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT03424005","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":"Metastatic Breast Cancer","enrollment":792},{"nctId":"NCT04347616","phase":"PHASE1, PHASE2","title":"Natural Killer-cell Therapy for Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2020-12-03","conditions":"Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, Relapsed, Adult","enrollment":9},{"nctId":"NCT04644770","phase":"PHASE1","title":"A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-11-12","conditions":"Prostatic Neoplasms, Adenocarcinoma","enrollment":144},{"nctId":"NCT05179876","phase":"PHASE3","title":"A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option","status":"RECRUITING","sponsor":"Actelion","startDate":"2022-05-04","conditions":"Hypertension, Pulmonary","enrollment":280},{"nctId":"NCT06193408","phase":"PHASE2","title":"Assessment of a Novel Fixed-dose Combination (FDC) Drug VR-AD-1005 for the Treatment of Acute Watery Diarrhea in Cholera","status":"COMPLETED","sponsor":"Hunazine Biotech S.L.","startDate":"2024-02-11","conditions":"Cholera","enrollment":150},{"nctId":"NCT07202546","phase":"PHASE2","title":"A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)","status":"RECRUITING","sponsor":"ViiV Healthcare","startDate":"2026-02-11","conditions":"HIV Infections","enrollment":150},{"nctId":"NCT04939610","phase":"PHASE1, PHASE2","title":"A Study of 177Lu-FAP-2286 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-07-30","conditions":"Solid Tumor","enrollment":222},{"nctId":"NCT05655312","phase":"PHASE1, PHASE2","title":"MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma","status":"RECRUITING","sponsor":"Perspective Therapeutics","startDate":"2023-06-01","conditions":"Recurrent Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV","enrollment":300},{"nctId":"NCT06234397","phase":"PHASE1","title":"Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2023-12-28","conditions":"Advanced or Metastatic Solid Tumors","enrollment":245},{"nctId":"NCT07464951","phase":"PHASE1","title":"CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Stephan Grupp MD PhD","startDate":"2026-04-01","conditions":"Acute Myeloid Leukemia (AML)","enrollment":30},{"nctId":"NCT02780128","phase":"PHASE1","title":"Next Generation Personalized Neuroblastoma Therapy","status":"TERMINATED","sponsor":"Yael P Mosse","startDate":"2016-07","conditions":"Neuroblastoma, Cancer","enrollment":66},{"nctId":"NCT07359105","phase":"NA","title":"Moderate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study)","status":"RECRUITING","sponsor":"Sin Gon Kim","startDate":"2026-03-09","conditions":"Dyslipidemia Associated With Type II Diabetes Mellitus","enrollment":2186},{"nctId":"NCT07219602","phase":"PHASE3","title":"A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome","status":"RECRUITING","sponsor":"NewAmsterdam Pharma","startDate":"2025-12-11","conditions":"Lipidemia, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS)","enrollment":300},{"nctId":"NCT05091567","phase":"PHASE3","title":"A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-11-18","conditions":"Small-Cell Lung Cancer","enrollment":660},{"nctId":"NCT02779855","phase":"PHASE1, PHASE2","title":"Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2017-05-02","conditions":"Breast Cancer, Ductal Carcinoma, Invasive Breast Carcinoma","enrollment":50},{"nctId":"NCT06499350","phase":"PHASE1, PHASE2","title":"A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors","status":"RECRUITING","sponsor":"FindCure Biosciences (ZhongShan) Co., Ltd.","startDate":"2024-11-13","conditions":"Advanced Malignant Solid Tumors","enrollment":33},{"nctId":"NCT05494580","phase":"PHASE1, PHASE2","title":"Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2022-09-22","conditions":"Ovarian Cancer, Ovarian Carcinoma, Platinum-resistant Ovarian Cancer","enrollment":29},{"nctId":"NCT05917509","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2023-07-06","conditions":"HIV Infections","enrollment":171},{"nctId":"NCT03999749","phase":"PHASE2","title":"A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2019-06-11","conditions":"Melanoma","enrollment":71},{"nctId":"NCT07223502","phase":"PHASE3","title":"A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease","status":"RECRUITING","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-12-01","conditions":"Hypertension (HTN)","enrollment":30},{"nctId":"NCT07374224","phase":"PHASE1","title":"A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib Tablet","status":"RECRUITING","sponsor":"Guangzhou Lupeng Pharmaceutical Company LTD.","startDate":"2026-03-05","conditions":"Clinical Pharmacology","enrollment":28},{"nctId":"NCT06646055","phase":"PHASE1, PHASE2","title":"AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2025-01-21","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":110},{"nctId":"NCT07454369","phase":"PHASE1","title":"Comparative Bioavailability Study Between Etoricoxib / Betamethasone Administered Individually or in Combination","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2022-10-24","conditions":"Healthy","enrollment":42},{"nctId":"NCT06031441","phase":"PHASE1","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2023-11-27","conditions":"Locally Advanced Solid Tumors, Recurrent Solid Tumors, Metastatic Solid Tumors","enrollment":250},{"nctId":"NCT07015671","phase":"PHASE3","title":"Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects","status":"COMPLETED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-07-01","conditions":"Bioequivalence Study in Healthy Subjects, PK/PD","enrollment":24},{"nctId":"NCT03075696","phase":"PHASE1, PHASE2","title":"A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-02-21","conditions":"Non-Hodgkin's Lymphoma","enrollment":940},{"nctId":"NCT06139796","phase":"PHASE1, PHASE2","title":"Pharmacokinetics Safety and Acceptability of DRV/r for Children Living With HIV","status":"WITHDRAWN","sponsor":"PENTA Foundation","startDate":"2025-02-01","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT06067828","phase":"PHASE3","title":"A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-10-24","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":171},{"nctId":"NCT06561386","phase":"PHASE3","title":"A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2024-10-07","conditions":"Non-small Cell Lung Cancer","enrollment":1000},{"nctId":"NCT07448142","phase":"PHASE2","title":"Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-15","conditions":"Colorectal Cancer (CRC)","enrollment":50},{"nctId":"NCT05068232","phase":"PHASE2","title":"Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2022-08-19","conditions":"Small-cell Lung Cancer, Extensive-stage Small-cell Lung Cancer, Lung Cancer","enrollment":49},{"nctId":"NCT03386617","phase":"PHASE2","title":"AKY15-HK-301_NEPA Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2018-02-27","conditions":"Breast Cancer","enrollment":55},{"nctId":"NCT06646276","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-02-25","conditions":"Extensive-Stage Small Cell Lung Cancer","enrollment":530},{"nctId":"NCT04895722","phase":"PHASE2","title":"Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-06-25","conditions":"Colorectal Cancer","enrollment":302},{"nctId":"NCT04215731","phase":"PHASE3","title":"Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Yanhong Deng","startDate":"2020-03-27","conditions":"Rectal Cancer","enrollment":582},{"nctId":"NCT04663347","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-03","conditions":"Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":543},{"nctId":"NCT07446725","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Safety, PK and Efficacy of GH55 in Combination With GH21 in Patients With Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Genhouse Bio Co., Ltd.","startDate":"2026-02-24","conditions":"Advanced Solid Tumor Cancer","enrollment":152},{"nctId":"NCT05153317","phase":"PHASE3","title":"Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-01-17","conditions":"Cystic Fibrosis","enrollment":71},{"nctId":"NCT07404137","phase":"PHASE1","title":"A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-02-16","conditions":"Healthy Participants","enrollment":26},{"nctId":"NCT07444619","phase":"PHASE1","title":"A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-08-31","conditions":"Soft Tissue Sarcomas","enrollment":18},{"nctId":"NCT06492954","phase":"PHASE1","title":"Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma","status":"RECRUITING","sponsor":"Emory University","startDate":"2026-03","conditions":"Osteosarcoma, Pulmonary Recurrence of Osteosarcoma","enrollment":12},{"nctId":"NCT04077723","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2019-08-13","conditions":"Lymphoma, Non-Hodgkin","enrollment":498},{"nctId":"NCT06759649","phase":"PHASE1","title":"A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies","status":"RECRUITING","sponsor":"Compugen Ltd","startDate":"2025-01-07","conditions":"Neoplasm, Cancer, Malignant Tumors","enrollment":200},{"nctId":"NCT06773910","phase":"PHASE2","title":"BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)","status":"RECRUITING","sponsor":"SCRI Development Innovations, LLC","startDate":"2025-03-11","conditions":"Limited Stage Small Cell Lung Cancer","enrollment":250},{"nctId":"NCT03589222","phase":"PHASE2","title":"SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2018-07-15","conditions":"Refractory Multiple Myeloma","enrollment":62},{"nctId":"NCT06836648","phase":"","title":"Single Patient Compassionate Use of X-PACT in Salvage Treatment of Prostate Cancer","status":"AVAILABLE","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT07432984","phase":"PHASE2","title":"Fecal Microbiota Transplant(FMT) Combination With Tislelizumab in Advanced or Metastatic NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Se-Hoon Lee","startDate":"2026-04-30","conditions":"Non Small Cell Lung Cancer","enrollment":15},{"nctId":"NCT07429565","phase":"PHASE1","title":"Testing APPA-1 in Healthy Subjects and Osteoarthritis Patients","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2018-04-09","conditions":"Osteoarthritis","enrollment":40},{"nctId":"NCT07430202","phase":"PHASE1","title":"A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)","status":"NOT_YET_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-05","conditions":"Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))","enrollment":27},{"nctId":"NCT05438420","phase":"PHASE1, PHASE2","title":"Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Qurient Co., Ltd.","startDate":"2023-01-12","conditions":"Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer","enrollment":120},{"nctId":"NCT06791434","phase":"PHASE4","title":"Assessing the Benefits of Dry Needling for Low Back Pain When Combined With Regular Treatment","status":"COMPLETED","sponsor":"Dr. Vishwanath Karad MIT World Peace University","startDate":"2024-08-30","conditions":"Low Back Pain","enrollment":156},{"nctId":"NCT05488522","phase":"PHASE1","title":"SBRT With Atezo/Bev for HCC","status":"RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2022-09-01","conditions":"Hepatocellular Carcinoma","enrollment":18},{"nctId":"NCT04526730","phase":"PHASE2","title":"Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2020-12-22","conditions":"Melanoma","enrollment":17},{"nctId":"NCT04024462","phase":"PHASE3","title":"A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-02-05","conditions":"HER2-positive Early Breast Cancer","enrollment":200},{"nctId":"NCT07422948","phase":"NA","title":"Efficacy and Safety of Early Initiation of Midodrine for Control and Prevention of Ascites and Its Related Complications in Acute-on-chronic Liver Failure.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-02-05","conditions":"Acute on Chronic Liver Failure","enrollment":113},{"nctId":"NCT07016412","phase":"PHASE2","title":"A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD","status":"RECRUITING","sponsor":"Verona Pharma plc","startDate":"2025-07-31","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":480},{"nctId":"NCT07421804","phase":"NA","title":"Evaluation of Topical Dutasteride as a Potential New Therapy for Facial Acne Vulgaris Versus the Triple Combination Therapy (Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel)","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-04","conditions":"Acne Vulgaris","enrollment":50},{"nctId":"NCT06999980","phase":"PHASE2","title":"Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)","status":"RECRUITING","sponsor":"Melanoma Institute Australia","startDate":"2026-02-09","conditions":"Cutaneous Melanoma, Mucosal Melanoma","enrollment":494},{"nctId":"NCT04223778","phase":"PHASE3","title":"Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-18","conditions":"HIV Infection","enrollment":672},{"nctId":"NCT04752826","phase":"PHASE1, PHASE2","title":"BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)","status":"RECRUITING","sponsor":"BioInvent International AB","startDate":"2021-01-25","conditions":"Advanced Malignancies, Ovarian Cancer, T-cell Lymphoma","enrollment":176},{"nctId":"NCT07417501","phase":"PHASE2","title":"Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2026-03-01","conditions":"Solid Tumors","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":304,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"fixed dose combination therapy","genericName":"fixed dose combination therapy","companyName":"University of Western Ontario, Canada","companyId":"university-of-western-ontario-canada","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}